Recombinant Anti-VEGFA antibody [EPR20705] (ab214424)
![Western blot - Anti-VEGFA antibody [EPR20705] (ab214424)](https://www.abcam.com/ps/products/214/ab214424/Images/ab214424-295234-anti-vegfa-antibody-epr20705-western-blot.jpg "Western blot - Anti-VEGFA antibody [EPR20705] (ab214424)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR20705] to VEGFA
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-VEGFA antibody [EPR20705]
See all VEGFA primary antibodies -
Description
Rabbit monoclonal [EPR20705] to VEGFA -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Human fetal vessel lysate; HeLa, HUVEC, SH-SY5Y, Neuro-2a, bEND.3, C6 and RAW 264.7 whole cell lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR20705 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab214424 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB |
1/1000. Detects a band of approximately 40 kDa (predicted molecular weight: 27 kDa).
|
| Notes |
|---|
|
WB
1/1000. Detects a band of approximately 40 kDa (predicted molecular weight: 27 kDa). |
Target
-
Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. -
Tissue specificity
Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. -
Involvement in disease
Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. -
Sequence similarities
Belongs to the PDGF/VEGF growth factor family. -
Cellular localization
Secreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. - Information by UniProt
-
Database links
- Entrez Gene: 7422 Human
- Entrez Gene: 22339 Mouse
- Entrez Gene: 83785 Rat
- Omim: 192240 Human
- SwissProt: P15692 Human
- SwissProt: Q96KJ0 Human
- SwissProt: Q00731 Mouse
- SwissProt: P16612 Rat
see all -
Alternative names
- Folliculostellate cell-derived growth factor antibody
- Glioma-derived endothelial cell mitogen antibody
- MGC70609 antibody
see all
Images
-
Western blot - Anti-VEGFA antibody [EPR20705] (ab214424)All lanes : Anti-VEGFA antibody [EPR20705] (ab214424) at 1/1000 dilution
Lane 1 : Human fetal vessel lysate
Lane 2 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 3 : HUVEC (human umbilical vein endothelial cell line) whole cell lysate
Lane 4 : SH-SY5Y (human neuroblastoma cell line from bone marrow) whole cell lysate
Lane 5 : Neuro-2a (mouse neuroblastoma cell line) whole cell lysate
Lane 6 : bEND.3 (mouse brain endothelioma cell line) whole cell lysate
Lane 7 : C6 (rat glial tumor cell line) whole cell lysate
Lane 8 : RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 27 kDa
Observed band size: 40 kDa why is the actual band size different from the predicted?Blocking/Dilution: 5% NFDM/TBST
Exposure time : Lanes 1-4/7-8: 3 minutes; Lane 5: 41 seconds; Lane 6: 15 seconds.
The blot was developed on a BIO-RAD® ChemiDoc™ MP instrument.
-
![Anti-VEGFA antibody [EPR20705] (ab214424)](https://www.abcam.com/ps/products/214/ab214424/Images/ab214424-2-benefits-of-recombinant-antibodies.png)
Anti-VEGFA antibody [EPR20705] (ab214424)
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (39)
ab214424 has been referenced in 39 publications.
- Duan Y et al. VEGF mitigates bisphosphonate-induced apoptosis and differentiation inhibition of MC3T3-E1 cells. Exp Ther Med 23:130 (2022). PubMed: 34970353
- Chen H et al. BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma. Int J Mol Sci 23:N/A (2022). PubMed: 35163396
- Chan TC et al. Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression. Cells 11:N/A (2022). PubMed: 35203290
- Lei S et al. In vivo three-dimensional multispectral photoacoustic imaging of dual enzyme-driven cyclic cascade reaction for tumor catalytic therapy. Nat Commun 13:1298 (2022). PubMed: 35277519
- Duan S et al. Peripheral Serum Exosomes Isolated from Patients with Acute Myocardial Infarction Promote Endothelial Cell Angiogenesis via the miR-126-3p/TSC1/mTORC1/HIF-1α Pathway. Int J Nanomedicine 17:1577-1592 (2022). PubMed: 35400999